Answers are grounded in this paper and cite their sources.
Significance A timely diagnosis is key for both survival and quality of life of children with CHARGE syndrome (coloboma, heart defects, atresia of choanae, retardation of growth/development, genital abnormalities, and ear anomalies). Such diagnosis is often difficult to establish, in part because many patients test negative for mutation of CHD7 , the only gene associated with this condition to date. Identifying additional CHARGE-associated genes would not only help resolve diagnosis issues but could also help in identifying common pathogenic mechanisms, which in turn could lead to desirable curative interventions for all patients. Here, FAM172A is reported as a new candidate gene for CHARGE syndrome. This discovery has allowed us to reveal a molecular process that is dysregulated in both CHD7 mutation-positive and -negative cases, such defect being correctable in vitro with rapamycin.
No takes yet. Share an insight, caveat, or question.
Bélanger et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: